Latest News and Press Releases

Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...

Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...

Key Points NMRC requests Pre-IND meeting with FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial...

MELBOURNE, Australia, April 28, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...

Key Highlights: North American sales up by 95% YoY in Q3 FY20Immuron achieved 60% YoY growth in worldwide product sales in Q3 FY20.YTD March 31, FY20 worldwide sales reached AU $2.67M, increasing 57%...

MELBOURNE, Australia, March 25, 2020 (GLOBE NEWSWIRE) -- The Directors and Management of Immuron wish to provide an update to the market regarding the current and future impact of COVID-19 on the...

Key Highlights: Strong continued growth of Travelan® sales reported in all marketsGlobal sales reached USD $1.1 million (AUD $1.68 million) for first half FY 2020 up 55% from first half FY 2019North...

Key Highlights: Wuhan coronavirus outbreak expanding to global health emergencyOutbreak while viral in nature highlights the role of global travel leading to respiratory and gastrointestinal...

Key Highlights: Strong continued growth of Travelan® sales reported in all marketsNorth American Travelan® sales up by 98% YoY in the first half of FY20Immuron achieved 55% YoY growth for the first...

MELBOURNE, Australia, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral...